1 active not recruiting, 1 completed, 1 recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
Follow BLU-5937: new trials by email Literature Review of BLU-5937 trials Research Report on BLU-5937
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension BLU-5937, Placebo - Refractory Chronic Cough | Phase 3 | Recruiting | GlaxoSmithKline | 75 | 2025-11-21 | 2026-06-16 |
| A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough BLU-5937, Placebo - Cough, Refractory Chronic Cough | Phase 3 | Active not recruiting | Bellus Health Inc. - a GSK company | 997 | 2022-12-05 | 2026-07-14 |
| A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough BLU-5937, Placebo - Cough, Refractory Chronic Cough | Phase 3 | Completed | Bellus Health Inc. - a GSK company | 957 | 2022-10-25 | 2026-07-14 |
Chronic Cough (3) · Cough (3) · Respiration Disorders (2) · Respiratory Tract Diseases (2) · Signs and Symptoms, Respiratory (2)
Bellus Health Inc. - a GSK company (2) · GlaxoSmithKline (1)
Canada (2) · China (2) · India (2) · United Kingdom (2) · United States (2) · Argentina (1) · Australia (1) · Belgium (1) · Colombia (1) · Czechia (1) · France (1) · Germany (1) · Hungary (1) · Israel (1) · Japan (1)